Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
254.21
-4.25 (-1.64%)
Jan 31, 2025, 4:00 PM EST - Market closed
Cencora Revenue
In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth. Cencora had revenue of $79.05B in the quarter ending September 30, 2024, with 14.69% growth.
Revenue (ttm)
$293.96B
Revenue Growth
+12.12%
P/S Ratio
0.17
Revenue / Employee
$6,390,404
Employees
46,000
Market Cap
49.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.95B |
COR News
- 5 days ago - Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients - Business Wire
- 19 days ago - Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth - Seeking Alpha
- 24 days ago - Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release - Business Wire
- 4 weeks ago - Cencora raises annual profit forecast - Reuters
- 4 weeks ago - Cencora Completes Acquisition of Retina Consultants of America - Business Wire
- 7 weeks ago - Cencora Closes $1.8 Billion Senior Notes Offering - Business Wire
- 2 months ago - Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers - Business Wire
- 2 months ago - Cencora: Competitive Advantages Defined - Seeking Alpha